Advancing Lentiviral Vector Yield, Quality & Commercial Readiness from Transient Transfection Platform to Stable Producer Cell Lines

11:00 am - Wednesday 25th February 2026

  • A robust lentiviral transient transfection platform delivering high, consistent yields at scale
  • Deep analytical profiling of LVV genome integrity and packaging efficiency to drive reliable, high‑quality vector production
  • Next‑gen LVV producer cell lines to enable high-volume supply with improved quality and lower COGS

Speakers:

Senior Director - Viral Vector, Cell Therapy, Research & Development
Lonza